Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Follow-up Scans Show Continued Stable Disease in First Patient Cohort


Company to Apply for FDA Fast Track Designation

...

Related Keywords

Beverly Hills ,Texas ,United States ,Houston ,Kiromic Biopharma ,Afshin Eli Gabayan ,Pietro Bersani ,Linkedin ,Kiromic Biopharma Inc ,Securities Exchange ,Beverly Hills Cancer Center ,Company Deltacel ,Twitter ,Drug Administration ,Gamma Deltat Cell ,Fast Track Designation ,Accelerated Approval ,Priority Review ,Chief Executive Officer ,Fast Track ,Breakthrough Therapy Designation ,Medical Oncologist ,Medical Director ,Principal Investigator ,Gamma Deltat Cell Infusions ,Subjects With Stage ,Non Small Cell Lung ,Beverly Hills Cancer ,Hills Cancer Center ,Gamma Deltat Cells ,Securities Exchange Act ,Annual Report ,